BRPI0813216A2 - Inibidores de proteínas cinases e métodos para usá-los. - Google Patents
Inibidores de proteínas cinases e métodos para usá-los.Info
- Publication number
- BRPI0813216A2 BRPI0813216A2 BRPI0813216-0A2A BRPI0813216A BRPI0813216A2 BR PI0813216 A2 BRPI0813216 A2 BR PI0813216A2 BR PI0813216 A BRPI0813216 A BR PI0813216A BR PI0813216 A2 BRPI0813216 A2 BR PI0813216A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- protein kinase
- kinase inhibitors
- inhibitors
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94541007P | 2007-06-21 | 2007-06-21 | |
| PCT/US2008/067290 WO2008157575A1 (en) | 2007-06-21 | 2008-06-18 | Protein kinase inhibitors and methods for using thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0813216A2 true BRPI0813216A2 (pt) | 2014-12-23 |
Family
ID=39682516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0813216-0A2A BRPI0813216A2 (pt) | 2007-06-21 | 2008-06-18 | Inibidores de proteínas cinases e métodos para usá-los. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110053932A1 (enExample) |
| EP (1) | EP2170842A1 (enExample) |
| JP (1) | JP2010530438A (enExample) |
| KR (1) | KR20100035635A (enExample) |
| CN (1) | CN101687821A (enExample) |
| AU (1) | AU2008265843B2 (enExample) |
| BR (1) | BRPI0813216A2 (enExample) |
| CA (1) | CA2691100A1 (enExample) |
| EA (1) | EA201000003A1 (enExample) |
| MX (1) | MX2009013781A (enExample) |
| WO (1) | WO2008157575A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2118074T3 (en) | 2007-02-01 | 2014-03-10 | Resverlogix Corp | Compounds for the prevention and treatment of cardiovascular diseases |
| EP2265610B1 (en) * | 2008-02-29 | 2012-12-12 | Array Biopharma, Inc. | Pyrazole [3, 4-b]pyridine raf inhibitors |
| EP2265574A1 (en) * | 2008-02-29 | 2010-12-29 | Array Biopharma, Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
| CN102015707A (zh) * | 2008-02-29 | 2011-04-13 | 阵列生物制药公司 | Raf抑制剂化合物及其使用方法 |
| WO2009111277A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Imdizo [4. 5-b] pyridine derivatives used as raf inhibitors |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| EP2300013B2 (en) | 2008-05-21 | 2024-11-13 | Takeda Pharmaceutical Company Limited | Phosphorous derivatives as kinase inhibitors |
| KR101709492B1 (ko) | 2009-03-18 | 2017-02-23 | 리스버로직스 코퍼레이션 | 신규한 소염제 |
| US9757368B2 (en) | 2009-04-22 | 2017-09-12 | Resverlogix Corp. | Anti-inflammatory agents |
| EP2937345B1 (en) * | 2009-12-29 | 2018-03-21 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| WO2011147764A1 (en) | 2010-05-28 | 2011-12-01 | N.V. Organon | Thieno (2, 3b) pyrazine compounds as b - raf inhibitors |
| WO2012037155A2 (en) * | 2010-09-13 | 2012-03-22 | Gtx, Inc. | Tyrosine kinase inhibitors |
| EP2704572B1 (en) | 2011-05-04 | 2015-12-30 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| EP3429307B1 (en) | 2011-08-10 | 2022-06-15 | Samsung Electronics Co., Ltd. | Method and apparatus for transmitting data using a multi-carrier in a mobile communication system |
| US10321419B2 (en) | 2011-08-10 | 2019-06-11 | Samsung Electronics Co., Ltd. | Method and apparatus for transmitting data using a multi-carrier in a mobile communication system |
| KR102247818B1 (ko) | 2011-08-10 | 2021-05-04 | 삼성전자 주식회사 | 이동통신 시스템에서 복수의 캐리어를 이용해서 데이터를 전송하는 방법 및 장치 |
| KR101967721B1 (ko) | 2011-08-10 | 2019-04-10 | 삼성전자 주식회사 | 무선 통신 시스템에서 확장 접속 차단 적용 방법 및 장치 |
| CN103858489A (zh) | 2011-10-05 | 2014-06-11 | 三星电子株式会社 | 在移动通信系统中选择相邻小区的方法和装置 |
| WO2013051858A2 (ko) | 2011-10-05 | 2013-04-11 | 삼성전자 주식회사 | 무선 통신 시스템에서 이종망 간 셀 재선택하는 방법 및 장치 |
| KR101996571B1 (ko) | 2011-10-10 | 2019-07-04 | 삼성전자 주식회사 | 이동통신 시스템에서 멀티 미디어 방송 서비스를 수신 방법 및 장치 |
| JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物 |
| WO2014060852A2 (en) * | 2012-10-15 | 2014-04-24 | Resverlogix Corp. | Compounds useful in the synthesis of benzamide compounds |
| KR20150123250A (ko) | 2013-03-06 | 2015-11-03 | 제넨테크, 인크. | 암 약물 내성의 치료 및 예방 방법 |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| EP3154589A1 (en) | 2014-06-13 | 2017-04-19 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
| WO2016073889A1 (en) | 2014-11-06 | 2016-05-12 | Lysosomal Therapeutics Inc. | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
| AU2015342883B2 (en) | 2014-11-06 | 2020-07-02 | Bial - R&D Investments, S.A. | Substituted pyrrolo(1,2-a)pyrimidines and their use in the treatment of medical disorders |
| CN107001379B (zh) | 2014-11-06 | 2022-11-01 | Bial研发投资股份有限公司 | 取代的吡唑并[1,5-a]嘧啶以及它们在治疗医学障碍中的用途 |
| US10111885B2 (en) | 2015-03-13 | 2018-10-30 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
| WO2017066193A1 (en) | 2015-10-15 | 2017-04-20 | Princeton Drug Discovery, Llc | Novel inhibitors of protein kinases |
| WO2017176962A1 (en) | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics, Inc. | Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| US10787454B2 (en) | 2016-04-06 | 2020-09-29 | BIAL—BioTech Investments, Inc. | Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| WO2017176960A1 (en) | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics Inc. | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| WO2017192929A1 (en) * | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | SUBSTITUTED PYRROLO[1,2-α]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| MX389579B (es) | 2016-05-05 | 2025-03-20 | Bial R&D Invest S A | IMIDAZO[1,2-b]PIRIDAZINAS SUSTITUIDAS, IMIDAZO[1,5-b]PIRIDAZINAS SUSTITUIDAS, COMPUESTOS RELACIONADOS Y SU USO EN EL TRATAMIENTO DE TRASTORNOS MÉDICOS |
| WO2017192931A1 (en) | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| WO2020140098A1 (en) | 2018-12-28 | 2020-07-02 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| CN112979615B (zh) * | 2019-12-17 | 2024-08-09 | 上海医药集团股份有限公司 | 一种喹唑啉脲类化合物、其制备方法、制备中间体、药物组合物及应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1218358B1 (en) * | 1999-09-23 | 2006-09-13 | AstraZeneca AB | Therapeutic quinazoline compounds |
| NZ522696A (en) * | 2000-06-28 | 2004-08-27 | Astrazeneca Ab | Substituted quinazoline derivatives and their use as inhibitors |
| AU2003270199A1 (en) * | 2002-09-13 | 2004-04-30 | Glaxo Group Limited | Urea compounds active as vanilloid receptor antagonists for the treatment of pain |
| WO2005105761A1 (en) * | 2004-04-28 | 2005-11-10 | Arrow Therapeutics Limited | Morpholinylanilinoquinazo- line derivatives for use as antiviral agents |
-
2008
- 2008-06-18 BR BRPI0813216-0A2A patent/BRPI0813216A2/pt not_active IP Right Cessation
- 2008-06-18 WO PCT/US2008/067290 patent/WO2008157575A1/en not_active Ceased
- 2008-06-18 US US12/665,894 patent/US20110053932A1/en not_active Abandoned
- 2008-06-18 EP EP08771318A patent/EP2170842A1/en not_active Withdrawn
- 2008-06-18 EA EA201000003A patent/EA201000003A1/ru unknown
- 2008-06-18 CA CA2691100A patent/CA2691100A1/en not_active Abandoned
- 2008-06-18 MX MX2009013781A patent/MX2009013781A/es active IP Right Grant
- 2008-06-18 JP JP2010513369A patent/JP2010530438A/ja active Pending
- 2008-06-18 AU AU2008265843A patent/AU2008265843B2/en not_active Expired - Fee Related
- 2008-06-18 KR KR1020097026460A patent/KR20100035635A/ko not_active Withdrawn
- 2008-06-18 CN CN200880021088A patent/CN101687821A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN101687821A (zh) | 2010-03-31 |
| AU2008265843B2 (en) | 2012-02-09 |
| EA201000003A1 (ru) | 2010-06-30 |
| EP2170842A1 (en) | 2010-04-07 |
| KR20100035635A (ko) | 2010-04-05 |
| CA2691100A1 (en) | 2008-12-24 |
| MX2009013781A (es) | 2010-02-01 |
| US20110053932A1 (en) | 2011-03-03 |
| JP2010530438A (ja) | 2010-09-09 |
| AU2008265843A1 (en) | 2008-12-24 |
| WO2008157575A1 (en) | 2008-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2019009I2 (el) | Αναστολεις πρωτεϊνικων κινασων | |
| IL280173A (en) | Inhibitors of brutons tyrosine kinase | |
| BRPI0910668A2 (pt) | inibidores de proteína quinases | |
| BRPI0812446A2 (pt) | Métodos para aperfeiçoamento de propriedades de proteína múltiplas | |
| BRPI0813356A2 (pt) | Inibidores de proteína quinase e métodos para uso dos mesmos | |
| BRPI0923159A2 (pt) | gene de delta-endotoxina axmi-150 e métodos para sua utilização. | |
| BRPI0819127A2 (pt) | Método para cimentar. | |
| ATE479434T1 (de) | Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine | |
| DK2099447T3 (da) | Imidazotriaziner og imidazopyrimidiner som kinaseinhibitorer | |
| EP2076128A4 (en) | PROTEIN CHINESE INHIBITOR AND ITS USE METHOD | |
| PT2004155T (pt) | Inibidores de agregação proteica | |
| EP1951684A4 (en) | BIARYLMETAPYRIMIDINKINASEINHIBITOREN | |
| BRPI1013623A2 (pt) | inibidores de ligação de proteína cinase | |
| IL210073A0 (en) | Protein kinase inhibitors | |
| CR10705A (es) | Anticuerpos para linfotoxina-alfa | |
| IL210069A0 (en) | Protein kinase inhibitors | |
| HUE056966T2 (hu) | Horonymarási eljárás | |
| DK2035385T3 (da) | Inhibitorer af akt (proteinkinase B) | |
| DK1976884T3 (da) | Anti-ephrinb2-antistoffer og fremgangsmåder til anvendelse deraf. | |
| ATE493403T1 (de) | Kinaseinhibitoren | |
| DK2170891T3 (da) | Pyrazolopyrimidinon-kinasehæmmere | |
| NO20084739L (no) | Substituerte 3-cyanopyridiner som protein kinase inhibitorer | |
| BRPI0719883A2 (pt) | Inibidores de quinase | |
| BRPI0907574A2 (pt) | Inibidores de ligação de proteína quinase | |
| LTC2379528I2 (lt) | Baltymų kinazės slopikliai |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |